Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | DPP4 | P27487 | 10/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | PDE5A | O76074 | 2/20 | 0.46 |
| ▸ | PDE6D | O43924 | 1/20 | 0.46 |
| ▸ | PDE6A | P16499 | 1/20 | 0.46 |
| ▸ | PDE6G | P18545 | 1/20 | 0.46 |
| ▸ | PDE6B | P35913 | 1/20 | 0.46 |
| ▸ | PDE6C | P51160 | 1/20 | 0.46 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18988050 | 0.95 | MEN1 (0.50) | MAPTGAATHRBDPP4MEN1 | |
| SCHEMBL30449564 | 0.90 | DPP4 (0.58) | MAPTGAATHRBDPP4MEN1 | |
| SCHEMBL2921747 | 0.90 | DPP4 (0.58) | MAPTGAATHRBDPP4MEN1 | |
| SCHEMBL30629571 | 0.89 | MAPT (0.62) | MAPTGAATHRBDPP4MEN1 | |
| SCHEMBL1467265 | 0.89 | KMT2A (0.61) | MAPTGAATHRBMEN1KMT2A | |
| SCHEMBL4651297 | 0.87 | DPP4 (0.52) | MAPTGAATHRBDPP4MEN1 | |
| SCHEMBL18987829 | 0.86 | CA2 (0.54) | MAPTGAATHRBMEN1KMT2A | |
| SCHEMBL30629545 | 0.86 | CA2 (0.54) | MAPTGAATHRBMEN1KMT2A | |
| SCHEMBL14358007 | 0.86 | DPP4 (0.51) | MAPTGAATHRBDPP4MEN1 | |
| SCHEMBL2913920 | 0.86 | MAPT (0.56) | MAPTGAATHRBDPP4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053104-B2 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | NPS PHARMACEUTICALS, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1595871-A2 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | NPS PHARMACEUTICALS, INC. (US) | 2005-11-16 | — | — | EP | disclosed |
| EP-1196397-B1 | METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS AND THEIR USE FOR TREATING CENTRAL NERVOUS SYSTEM DISEASES | NPS PHARMA INC (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20030013715-A1 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | NPS PHARMACEUTICALS, INC. | 2003-01-16 | — | — | US | disclosed |
| US-6429207-B1 | QUINOXALINE DERIVATIVES EXHIBITING A HIGH DEGREE OF POTENCY AND SELECTIVITY FOR INDIVIDUAL METABOTROPIC GLUTAMATE RECEPTORS (MGLUR) | NPS PHARMACEUTICALS, INC. | 2002-08-06 | — | — | US | disclosed |
| EP-1196397-A1 | METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS AND THEIR USE FOR TREATING CENTRAL NERVOUS SYSTEM DISEASES | NPS PHARMACEUTICALS, INC. (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2000073283-A1 | METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS AND THEIR USE FOR TREATING CENTRAL NERVOUS SYSTEM DISEASES | NPS PHARMACEUTICALS, INC. (US) | 2000-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013715-A1 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | GRM2, GRM1, GRM3 | MAPT 471/4885GAA 1029/4885THRB 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.